Hyderabad\/New Delhi:<\/strong> Indian pharmaceutical companies witnessed sharp selling pressure on Wednesday after US President Donald Trump announced a phased tariff plan on imported generic medicines, triggering concerns over the future of India’s pharmaceutical exports to the United States.<\/p>\n\n\n\n The Nifty Pharma Index<\/strong> dropped nearly 2% in early trade<\/strong>, making it the worst-performing sectoral index on the National Stock Exchange (NSE). The index fell 1.85% to 25,610<\/strong>, while the benchmark Nifty 50<\/strong> declined 0.70% (169 points) to 24,017<\/strong>.<\/p>\n\n\n\n Selling was witnessed across the pharmaceutical sector, with Gland Pharma<\/strong> emerging as the biggest loser, declining 4.54%<\/strong>. Other major losers included:<\/p>\n\n\n\n Among the Nifty 50 constituents, Cipla, Sun Pharma, and Dr. Reddy’s Laboratories<\/strong> were among the top early losers.<\/p>\n\n\n\n According to President Trump, the United States will introduce tariffs on imported generic medicines in phases:<\/p>\n\n\n\n Trump stated that the phased approach is intended to encourage pharmaceutical manufacturers to relocate production facilities to the United States. He also clarified that the tariff policy would apply only to generic medicines<\/strong>, while patented and branded drugs<\/strong> would remain unaffected.<\/p>\n\n\n\n India is one of the world’s largest exporters of affordable generic medicines, with the United States being its biggest overseas market. The proposed tariff structure has raised concerns about the long-term competitiveness of Indian drug manufacturers that derive a significant portion of their revenue from US exports.<\/p>\n\n\n\n Market analysts, however, believe that relocating generic drug manufacturing to the US may not be an immediate solution. Producing generic medicines in the United States is estimated to cost 25\u201330% more<\/strong> than manufacturing in India. They also noted that establishing new manufacturing facilities and regulatory approvals within the proposed two-year transition period would be challenging.<\/p>\n\n\n\n While the phased implementation provides companies some time to adjust their manufacturing strategies, investors remain cautious about the potential impact on export earnings and profit margins. The announcement has renewed uncertainty over the outlook for India’s pharmaceutical sector, which has long benefited from strong demand for low-cost generic medicines in the US market.<\/p>\n\n\n\n As the policy details evolve, pharmaceutical companies are expected to closely evaluate supply chain adjustments, investment plans, and manufacturing diversification to mitigate the impact of the proposed tariffs.<\/p>\n","protected":false},"excerpt":{"rendered":" Hyderabad\/New Delhi: Indian pharmaceutical companies witnessed sharp selling pressure on Wednesday after US President Donald Trump announced a phased tariff plan on imported generic medicines, triggering concerns over the future of India’s pharmaceutical exports to the United States. The Nifty Pharma Index dropped nearly 2% in early trade, making it the worst-performing sectoral index on […]<\/p>\n","protected":false},"author":1,"featured_media":28328,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_post_was_ever_published":false},"categories":[74,14,1],"tags":[],"class_list":["post-28326","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","category-international","category-politics"],"yoast_head":"\nBroad-Based Selling Across Pharma Stocks<\/h3>\n\n\n\n
\n
Trump’s Phased Tariff Plan<\/h3>\n\n\n\n
\n
Impact on Indian Pharmaceutical Industry<\/h3>\n\n\n\n
Market Outlook<\/h3>\n\n\n\n